Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers

Fig. 3

Effect of PS-targeting and anti-PD-1 antibody therapy on survival in a TNBC murine model. Mice with E0771 tumors were treated a total of six times once tumors reached approximately 100 mm3 (days 1, 4, 8, 11, 15, and 18) with single antibody or a combination of mch1N11 and anti-PD-1, and survival times were determined. Once tumors reached approximately 1500 mm3 or animals encountered a tumor-related health problem, animals were euthanized. Survival times were plotted and determined by Kaplan–Meier analysis, statistical analysis was determined by log rank (Mantel–Cox) analysis

Back to article page
\